CureVac N.V. stock is up 1.46% since 30 days ago. The next earnings date is Apr 25, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 CALL.
CureVac N.V. focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA) It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV and CV7202. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma.